Difference between revisions of "Prothrombin complex concentrates"
(→Sources) |
(→General) |
||
Line 1: | Line 1: | ||
==General== | ==General== | ||
− | *Type: Hemostatics, blood components | + | *Type: Hemostatics, [[blood components]] |
*Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial | *Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial | ||
*Common Trade Names: Kcentra | *Common Trade Names: Kcentra |
Revision as of 17:34, 29 May 2015
Contents
General
- Type: Hemostatics, blood components
- Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
- Common Trade Names: Kcentra
Adult Dosing
- Based on pretreatment INR, units based on factor 9 content
- INR 2-4: 25units/kg, not to exceed 2500 units
- INR 4-6: 35units/kg, not to exceed 3500 units
- INR >6: 50units/kg, not to exceed 5000 units
Pediatric Dosing
Safety and efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown, breast feeding not advised
- Renal Dosing
- Adult-N/A
- Pediatric-N/A
- Hepatic Dosing
- Adult-N/A
- Pediatric-N/A
Contraindications
Serious
- thromboembolism
- blood product (hepatitis, HIV)
Common
- thromboembolic events (8.7%)
- headache (7.8%)
- hypotension (4.9%)
- nausea/vomiting
- arthralgia
- ICH (2.9%)
- mental status change (2.9%)
- hypertension (2.9%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: